Abstract: Surfactants based on a newly discovered class of compounds include a hydrophobic lipid oligomer covalently linked to a peptide or peptide-like chain and a carbohydrate moiety, and a serine-leucinol dipeptide linked to the lipid oligomer. Such surfactants can be used to create an oil-in-water or water-in-oil emulsion by mixing together a polar component; a non-polar component; and the surfactant. Biosurfactants of the newly discovered class can be made by isolating and culturing a microorganism which produces the biosurfactant, and then isolating the biosurfactant from the culture. A microorganism can be engineered to produce biosurfactant of this newly discovered class by expressing a set of heterologous genes involved in the biosynthesis of the biosurfactant in the microorganism.

Abstract: Processes and systems for recovering products from a fermentation mash. In some examples, a process for recovering products from a fermentation mash can include processing a ground corn product to produce a fermentation mash that can include ethanol. At least a portion of the ethanol can be separated from the fermentation mash to produce a whole stillage. The whole stillage can be separated to produce a fiber rich product and a filtrate. The fiber rich product can be hydrolyzed to produce a saccharification mash. The saccharification mash can be processed to produce additional ethanol and a stillage protein product.

Abstract: Disclosed herein are media for culture of cells, tissues, and/or organs. The media formulations disclosed herein can be used to support growth, viability, and/or function of one or more than one cell type, tissue, or organ. In some embodiments, one or more cell types, tissues, organ devices, and/or organs are contacted with a disclosed culture medium under conditions sufficient to support growth, viability, and/or function of the cell types, tissues, and/or organs. The disclosed media can be used in methods of culturing multiple cell types, and in some examples, is used in a platform device including one or more organ devices, for example, by circulating the medium through the one or more organ devices in the platform.

Abstract: The present disclosure generally relates to biological platforms for the conversion of cellulosic biomass into fuels and chemicals. More specifically, the present disclosure relates to the conversion of cellulosic materials into sugar acids or their salts, which may then be used to produce commodity chemicals. In one aspect, the present disclosure relates to a recombinant host cell including: reduced activity of one or more polypeptides having P-glucosidase activity as compared to a corresponding wild type cell, where each of said one or more polypeptides are encoded by a gene that has at least 80% sequence identity to a gene.

Abstract: A food grade water-soluble arabinoxylan product containing arabinoxylan oligosaccharides and retaining a high amount of bound ferulic acid and other phenolic substances is isolated from corn fiber using an aqueous extraction wherein the pH of the aqueous medium employed for the extraction is adjusted to a selected value after mixing with the corn fiber and prior to the initiation of extraction.

Abstract: The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi.

Abstract: The present invention aims to provide a method for producing a polysaccharide with high efficiency using a polysaccharide synthase. The present invention provides a method for producing a polysaccharide, including allowing polysaccharide synthase (B) to act on ribonucleoside diphosphate-monosaccharide (A) to produce a polysaccharide, wherein in 10 to 100% of the duration in which (B) acts on (A), the concentration of ribonucleoside diphosphate in a reaction solution is lower than 100 times an inhibitory concentration IC50 against polysaccharide synthase (B).

Abstract: A process for isolating rhamnolipids is provided. The process includes providing an aqueous medium containing at least one rhamnolipid and having a pH of less than 6. Next, the aqueous medium is brought into contact with at least one organic solvent to provide a multiphase system and then the aqueous phase is separated off. The pH is then increased to a value of 6 or more to provide a multiphase organic system. Next, a rhamnolipid-enriched organic phase is separated off. An optional step of further purifying the rhamnolipid may be performed.

Abstract: The isolation and characterization of a glucosyltransferase gene from Candida bombicola is disclosed. Use of the glucosyltransferase enzyme for the production of glucosylated sterol and hydroxyl-fatty acid substrates is also disclosed. This enzyme has broad-specificity and is useful for the production of sophorolipids both in-vivo and in-vitro.

Abstract: A functional soap includes nanoscale platinum, gold, silver, organic germanium and organic selenium to prepare soap, wherein anti-bacterial, sterilizing, skin irritation relieving and skin moisturizing functions provided in platinum, gold, silver, organic germanium, and organic selenium are added to the washing effect of the conventional soap.

Abstract: The present invention provides novel and advantageous materials and methods for preventing and treating viral infection.

Abstract: A method for detection of beta-D-glucuronidase activity in a sample that comprises the steps of (i) providing a glucuronic acid ester compound of the general formula (I) wherein R1 is a C1-4 alkyl group, OR2 is a dye moiety, which is liberated after cleavage of the glycosidic bond; (ii) contacting said glucuronic acid ester compound with a material of said sample exhibiting hydrolytic activity towards glucuronic acid esters, thereby removing R1 and thus forming a sample containing an indicator compound suitable for the detection and/or measurement of beta-D-glucuronidase activity, and (iii) using said indicator to perform an assay requiring detection or measurement of beta-D-glucuronidase activity.

Abstract: The present invention embraces a recombinant prokaryotic host cell containing nucleic acids encoding an eukaryotic UDP-GaINAc:UDP-GaINAc polypeptide transferase and expressing an UDP-GIcNAc C-4 epimerase and methods for using the same to produce an O-glycosylated protein.

Abstract: The present invention relates to methods of use of glycosyltransferases and related novel compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomolecules and numerous one-pot reactions for generation of new biomolecules having varied backbones such as enediynes, vancomycins, bleomycins, anthracyclines, macrolides, pluramycins, aureolic acids, indolocarbazoles, aminglycosides, glycopeptides, polyenes, coumarins, benzoisochromanequinones, calicheamicins, erythromycin, avermectins, ivermectins, angucyclines, cardiac glycosides, steroids or flavinoids. In preferred embodiments, the invention specifically relates to biosynthesis of anticancer (the enediyne calicheamicin, CLM), anthelmintic agents (the macrolides avermectin, ivermectin and erythromycin) and antibiotic (the glycopeptide vancomycin, VCM) natural product-based drugs developed by reversible, bidirectional glycosyltransferase-catalyzed reactions.

Abstract: The object of the present invention is to provide Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides a transformant transformed with a gene for Humulus lupulus-derived monoterpene glycosyltransferase and a method for producing such a transformant.

Abstract: The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor. The application further discloses a method for producing an oligosaccharide comprising the steps of: (a) culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor to produce an anomerically protected glycosidic oligosaccharide derivative, then (b) removing/deprotecting the anomeric protective group.

Abstract: A process for enzymatically converting a furanoside substrate in a product of interest, includes contacting the substrate with an enzyme in presence of an alcohol acceptor, wherein the enzyme is preferably Araf51, and wherein the product is preferably an alkyl furanoside. The mutant Araf51 enzyme showing improved transglycosylation activity in comparison with the native wild-type (wt) Araf51 enzyme, and a method for screening the mutants are also described.

Abstract: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon ?2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation.

Abstract: The invention provides a process of producing Rubusoside from steviol glycosides of Stevia rebaudiana plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike.

Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).

Abstract: The invention relates to cells and nucleic acids and also use thereof for producing rhamnolipids, and also methods for producing rhamnolipids.

Abstract: A method for producing metabolites of Crocus sativus (C. sativus) includes (i) selecting a cell line of C. sativus that produces one or more saffron metabolites in cell suspension culture, and (ii) growing the selected cell line in a suspension cell culture to produce the saffron metabolite.

Abstract: This invention provides nucleoside triphosphate analogues having the structure: wherein B is a base and is adenine, guanine, cytosine, uracil or thymine, wherein R? is an OH or an H, and wherein R? is azidomethyl, a hydrocarbyl, or a substituted hydrocarbyl, and which has a Raman spectroscopy peak with wavenumber from 2000 cm?1 to 2300 cm?1 or a Fourier transform-infrared spectroscopy spectroscopy peak with wavenumber from 2000 cm?1 to 2300 cm?1, and also to methods of DNA sequencing and SNP detection.

Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Abstract: The invention provides novel gangliosides and mixtures of novel gangliosides, and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

Abstract: This invention provides novel enzyme compositions using newly identified and isolated C. lucknowense enzymes, including CBH Ib CBH IIb, EG II, EG VI, ?-glucosidase, and xylanase II in conjunction with previously identified enzymes CBH Ia, CBH IIa (previously described as Endo 43), and EG V. These enzyme compositions demonstrate an extremely high ability to convert lignocellulosic biomass (e.g., Avicel, cotton, Douglas fir wood pretreated by organosolv) to glucose. CBH Ia and IIb, which both have a cellulose-binding module (CBM) displayed a pronounced synergism with three major endoglucanases (EG II, EG V, EG VI) from the same fungus in hydrolysis of cotton as well as a strong synergy with each other. The enzyme compositions are effective in hydrolysis of the lignocellulosic biomass.

Abstract: Fermentation media containing an isoflavone-depleted soybean meal or isoflavone-depleted soybean meal product and at least one exogenous added ingredient that comprises a substrate for microbial growth are provided. Methods of making a fermentation medium comprising an isoflavone-depleted soybean meal or isoflavone-depleted soybean meal product and methods for obtaining a fermentation product are also provided. The present invention is further directed to fermentation broths obtained by the media and methods. The present invention is also directed to feed additives produced from fermentation broths obtained by the methods.

Abstract: Foods and beverages, quasi-drugs, and pharmaceuticals that exhibit high antioxidative activity in the living body for a long time are provided. High antioxidative activity can be imparted by incorporating desrhamnosyl acteoside in an olive extract. A desrhamnosyl acteoside-containing composition can be prepared by treating an acteoside-containing composition with glycosidase.

Abstract: An in vitro method to produce a glycoside is described which includes the steps of contacting the cellodextrin phosphorylase from Clostridium stercorarium with alpha-glucose-1-phosphate or alpha-galactose-1-phosphate and an acceptor, and glycosylating the acceptor. The acceptor may be an alkyl beta-glucoside, an aryl beta-glucoside, a glucolipid, an alkyl beta-sophoroside, an aryl beta-sophoroside or a sophorolipid. Alkylcellobiosides, arylcellobiosides, cellobiolipids, cellotriolipids, glucosophorolipids and cellobiosesophorolipids are produced when alpha-glucose-1-phosphate is used as donor. Corresponding lactosides are produced when alpha-galactose-1-phosphate is used as donor.

Abstract: The present disclosure relates to an enzyme derived from Candida bombicola that is capable of lactonizing or polymerizing carbohydrate-containing compounds, lipids, fatty acids, hydroxylated fatty acids, alcohols, dicarboxylic acids or mixtures thereof. Hence, host cells comprising the latter enzyme can be used, via the formation of intra- or inter-molecular ester-bounds, to produce, for example, lactonized sophorolipids or polymers of acidic sophorolipids. On the other hand, host cells having lost their capability to produce a functional enzyme disclosed herein can be used to produce 100% acidic sophorolipids.

Abstract: The present invention relates to Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase and use thereof. The polypeptide has an activity of converting PPD (protopanaxadiol)-type saponins into in vivo absorbable and highly active deglycosylated saponins, by selective hydrolysis of a bond at a particular position of ginsenoside. The present invention also relates an amino acid sequence constituting the polypeptide, a nucleic acid sequence encoding the protein, a recombinant vector comprising the nucleic acid sequence, and a transformant transformed with the vector. The invention further provides a method for preparing Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase by culturing the transformant, a method for converting PPD (protopanaxadiol)-type major ginsenoside into a rare ginsenoside that is absorbable in vivo using the protein, and a composition for converting PPD-type saponins into in vivo absorbable saponins, having the protein as an active ingredient.

Abstract: The invention relates to a mixture composition comprising rhamnolipids, to a process for its preparation, to its use for producing formulations and to formulations comprising this mixture composition.

Abstract: This invention provides a method for preparing cycloastragenol monoglucoside CMG (cycloastragenol-6-O-?-D-glucoside), comprising the steps of: a. using astragaloside IV or Astragali extracts prepared by a conventional method as raw materials and adding an appropriate solvent thereinto to form a raw material solution; b. adding hydrolase and allowing for hydrolysis at a constant temperature to obtain a hydrolysate; c. separating the hydrolysate with macroporous adsorption resin; and d. obtaining the product by purification and separation. The present invention further provides cycloastragenol-6-O-?-D-glucoside prepared according to the method of this invention as well as its use in the preparation of a medicament for treating cardiovascular diseases and pharmaceutical compositions comprising the same.

Abstract: The invention provides novel methods and compositions directed to farnesol production, accumulation and cellular sequestration in plants. More specifically, the methods of the invention comprise modifying plant cells that express farnesene to convert the farnesene to farnesol, and in some cases, to farnesol glycoside, such as farnesol glucoside. In other embodiments, carbon flux is shunted towards sesquiterpene production by applying certain plant growth regulators and herbicides to increase sesquiterpene production.

Abstract: The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal ?-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.

Abstract: The present invention provides a novel sialo-sugar chain, a process for producing the sialo-sugar chain, and a device for producing the sialo-sugar chain. A sialo-sugar chain can be easily and efficiently mass-produced by reacting a sugar wherein a hydroxy groups is substituted with an alkynyl group (herein sometimes referred to as “alkynylated sugar”) with a specific sialic acid donor in the presence of a sialic acid-introducing enzyme.

Abstract: Provided is a host cell comprising a rhlA gene or an ortholog thereof, under the control of a heterologous promoter and a rhlB gene or an ortholog thereof, under the control of a heterologous promoter. The host cell is capable of achieving a carbon yield of more than 0.18 Cmol rhamnolipid/Cmol substrate. Provided is also a method of producing rhamnolipids, employing such a host cell.

Abstract: Enzyme compositions including at least a) a cocktail of cellulases from Trichoderma reesei, and b) an enzymatic cocktail from Pycnoporus cinnabarinus including a cellobiose dehydrogenase (CDH) or c) a recombinant cellobiose dehydrogenase (CDH) from Pycnoporus cinnabarinus, preferably also including a Family 61 glycoside hydrolase. Also, methods for degrading a lignocellulosic biomass, for producing a fermentation product, for producing gluconic acid, xylonic acid and/or xylobionic acid, for enhancing the production of gluconic acid, xylonic acid and/or xylobionic acid or for increasing the yield of sugars from a lignocellulosic biomass.

Abstract: The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid, -continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the reaction mixture below 10 g/l, resulting in the crystallization of at least part of the sophorolactone present in the reaction mixture, -warming the reaction mixture to a temperature between 60° C. and 90° C.

Abstract: The present invention aims to provide a particulate composition containing anhydrous crystalline 2-O-?-D-glucosyl-L-ascorbic acid having a significantly, hardly solidifiable property compared to conventional ones in a grade for use in quasi-drugs; a process for producing the same; and uses thereof. The present invention solves the above object by providing a particulate composition containing anhydrous crystalline 2-O-?-D-glucosyl-L-ascorbic in an amount of over 98.0% by weight but less than 99.9% by weight, on a dry solid basis; or a degree of crystallinity of 90% or higher for anhydrous crystalline 2-O-?-D-glucosyl-L-ascorbic acid; and by providing a process for producing the same and uses thereof.

Abstract: A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, including the steps of: (a) constructing a recombinant plasmid including a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I-producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively including a single gene ist.

Abstract: The object of the present invention is to provide a method and a process for producing 2-O-?-glucopyranosyl-L-ascorbic acid where 5-O-?-glucopyranosyl-L-ascorbic acid and 6-O-?-glucopyranosyl-L-ascorbic acid are not formed or formed in such a small amount that the formation of these can nor be detected. The present invention solves the above object by providing a process for producing 2-O-?-glucopyranosyl-L-ascorbic acid comprising the steps of allowing ?-isomaltosyl glucosaccharide-forming enzyme together with or without cyclomaltodextrin glucanotransferase (EC 2.4.1.19) to act on a solution comprising L-ascorbic acid and, an ?-glucosyl saccharide to form 2-O-?-glucopyranosyl-L-ascorbic acid and collecting the formed 2-O-?-glucopyranosyl-L-ascorbic acid.

Abstract: A compound having a structure expressed by the following Structural Formula (1), tautomers thereof, or salts of the compound or the tautomers.

Abstract: A method to increase the production of products of interest in plant material including plant cultures, such as, for example, cell suspension cultures, root cultures, and hairy root cultures is provided. In one embodiment, the method is to contacting the plant material with a precursor or xenobiotic when producing a product of interest from a plant. In another embodiment the plant material is also contacted with a trapping agent. The process may also provide for contacting an elicitor of the product of interest with the plant material. An embodiment provides for contacting an elicitor, precursor and trapping agent with the plant material. The ability to produce novel compounds such as glucosides and glucuronides is provided.

Abstract: The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-?-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application.

Abstract: The object is to provide a transformant which can produce a heterologous protein having a structurally controlled O-linked sugar chain having an O-Man-Gal disaccharide structure, a method for producing the transformant by using Schizosaccharomyces pombe as the host, and provide a host for producing the transformant and a method for producing an O-glycosylated heterologous protein. An Schizosaccharomyces pombe host having no omh1 gene or an inactivated omh1 gene in its chromosomes for producing an O-glycosylated heterologous protein having an O-linked sugar chain having an O-Man-Gal disaccharide structure by expression of the heterologous protein by a genetic engineering technique and subsequent glycosylation of the expressed heterologous protein. A transformant from the host, a method for producing the transformant and a method for producing an O-glycosylated heterologous protein by using the transformant.